Literature DB >> 35226350

Weekly Supervised Administration of Oral Antipsychotics: An Alternative to Long-Acting Injections?

Sofia Brissos1,2, David Taylor3,4.   

Abstract

Maintenance of response in schizophrenia is largely dependent on compliance with antipsychotic treatment. When people with schizophrenia are responsible for their own treatment, partial or non-adherence is common and usually results in relapse. Assured compliance with antipsychotic treatment is possible when long-acting injectable antipsychotics are given by healthcare staff, but some patients may not consent to treatment for a variety of reasons. An alternative to long-acting injections is the use of supervised oral administration of long-acting antipsychotics. This method assures compliance with prescribed regimens without the need for injections. To be suitable for once-weekly administration as an oral formulation, an antipsychotic needs to have a sufficiently long duration of action and to be well tolerated in high doses. There is evidence that weekly oral administration of either pimozide or penfluridol is effective and well tolerated in the treatment of schizophrenia. Other drugs potentially suitable for once-weekly oral administration include aripiprazole, brexpiprazole and cariprazine.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35226350     DOI: 10.1007/s40263-022-00906-4

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  51 in total

1.  A FOLLOW-UP OF SCHIZOPHRENIC PATIENTS IN EDINBURGH.

Authors:  C A Renton; J W Affleck; G M Carstairs; A D Forrest
Journal:  Acta Psychiatr Scand       Date:  1963       Impact factor: 6.392

Review 2.  Medication adherence in schizophrenia.

Authors:  Francisco Javier Acosta; José Luis Hernández; José Pereira; Judit Herrera; Carlos J Rodríguez
Journal:  World J Psychiatry       Date:  2012-10-22

3.  Using Long-Acting Injectable Antipsychotics to Enhance the Potential for Recovery in Schizophrenia.

Authors:  Christoph U Correll; John Lauriello
Journal:  J Clin Psychiatry       Date:  2020-06-30       Impact factor: 4.384

4.  Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication.

Authors:  R F Prien; J O Cole; N F Belkin
Journal:  Br J Psychiatry       Date:  1969-06       Impact factor: 9.319

5.  20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20).

Authors:  Heidi Taipale; Antti Tanskanen; Juha Mehtälä; Pia Vattulainen; Christoph U Correll; Jari Tiihonen
Journal:  World Psychiatry       Date:  2020-02       Impact factor: 49.548

6.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Authors:  Jeffrey A Lieberman; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Sonia M Davis; Clarence E Davis; Barry D Lebowitz; Joanne Severe; John K Hsiao
Journal:  N Engl J Med       Date:  2005-09-19       Impact factor: 91.245

Review 7.  Advances in psychotropic formulations.

Authors:  Samuel Keith
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2006-05-06       Impact factor: 5.067

Review 8.  The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses.

Authors:  Peter M Haddad; Christoph U Correll
Journal:  Ther Adv Psychopharmacol       Date:  2018-10-08

Review 9.  Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review.

Authors:  Robert B Zipursky; Natasja M Menezes; David L Streiner
Journal:  Schizophr Res       Date:  2013-08-21       Impact factor: 4.939

10.  The Impact of Antipsychotic Formulations on Time to Medication Discontinuation in Patients with Schizophrenia: A Dutch Registry-Based Retrospective Cohort Study.

Authors:  Arnold P M van der Lee; Ibrahim Önsesveren; André I Wierdsma; Roos van Westrhenen; Aartjan T F Beekman; Lieuwe de Haan; Niels C L Mulder
Journal:  CNS Drugs       Date:  2021-04-10       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.